Lung Cancer

Early treatment with epoetin alfa maintains hemoglobin levels during chemotherapy

Published in Cancer Weekly, September 23rd, 2003

Patients who receive epoetin alfa from the outset of chemotherapy for advanced non-small-cell lung cancer (NSCLC) maintain normal hemoglobin (Hb) levels (>12 g/dl), with minimized impact of chemotherapy on quality of life (QoL), according to a study released at the World Congress of Lung Cancer in Vancouver, Canada.

Dr. Robert Milroy, Stobhill Hospital, Glasgow, Scotland, lead investigator of the study, said, "Only NSCLC patients in the study arm receiving early intervention (Hb 12-13 g/dl) with epoetin alfa maintained or increased Hb levels during chemotherapy. It is important that oncologists recognize the benefits of proactive anemia management and optimal Hb...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-09-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry